Navigation Links
Tiens Biotech Group (USA) Reports First Quarter Results
Date:5/17/2010

38,037 11,236,501 Total non current liabilities 11,238,037 11,236,501 Total liabilities 49,886,084 45,334,533 EQUITY: Shareholders' equity of the Company: Common stock, $0.001 par value, 250,000,000 shares authorized, 71,333,586 issued and outstanding, respectively 71,334 71,334 Paid-in-capital 18,118,007 18,042,189 Statutory reserves 13,217,217 13,217,217 Retained earnings 129,631,801 126,370,263 Accumulated other comprehensive income 18,277,093 18,262,123 Total shareholders' equity of the Company 179,315,452 175,963,126 Noncontrolling interest 10,161,377 9,812,049 Total equity 189,476,829 185,775,175 Total liabilities and equity $239,362,913 $231,109,708 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009 (UNAUDITED) Three months ended March 31, 2010 2009 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $3,603,595 $8,999,799 Adjustments to reconcile net income to cash provided by (used in) operating activities: Provision for doubtful accounts 202,247 (184,568) Depreciation 417,469 544,811 Amortization 83,557 97,143 Interest expense
'/>"/>
SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
5. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
6. Cutting-Edge Vaccine Research to be Showcased at AAPS National Biotechnology Conference
7. Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership
8. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
11. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... BERKELEY HEIGHTS, N.J., June 5 Genta,Incorporated (OTC Bulletin ... into definitive agreements with institutional and accredited,investors to ... in,aggregate up to $40 million in gross proceeds ... $20 million of Notes is expected to take ...
... Life Sciences Inc.,(TSX: PLI) ("ProMetic") announced today that ... earlier this year with the Wuhan,Institute of Biological ... ("CNBG") was held on Wednesday, June 4, 2008 ... were CNBG,s President and Chief Executive,Officer Ms. Lifeng ...
... 2009 and ... ... serve as an ideal launching pad that positions the company for,new ... Monsanto,s executive vice president of global,commercial, will tell investors today at ...
Cached Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4Official Signing Ceremony for WIBP Strategic Alliance 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 3Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 4
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... that can sail throughout the body via the bloodstream ... and ferry their cargo of anti-cancer drugs and markers ... In a forthcoming issue of the Germany-based chemistry ... Diego, UC Santa Barbara and MIT report that their ...
... this goal, scientists at the OU Cancer Institute have found ... they can target the cells and kill them, keeping cancer ... of Oklahoma led by Courtney Houchen, M.D., and Shrikant Anant, ... cells. Until now, researchers knew of proteins that appeared in ...
... -- What,s the worst that could happen after eating a ... But for up to a million women in the ... have a chronic bladder condition that causes pelvic pain. Spicy ... can cause a flare in their symptoms and intensify the ...
Cached Biology News:Researchers develop nano-sized 'cargo ships' to target and destroy tumors 2Researchers develop nano-sized 'cargo ships' to target and destroy tumors 3Researchers develop nano-sized 'cargo ships' to target and destroy tumors 4The pepperoni pizza hypothesis 2The pepperoni pizza hypothesis 3
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Biology Products: